| __timestamp | Arrowhead Pharmaceuticals, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 1244910 |
| Thursday, January 1, 2015 | 34718089 | 5029636 |
| Friday, January 1, 2016 | 40998209 | 4846776 |
| Sunday, January 1, 2017 | 32022880 | 5329003 |
| Monday, January 1, 2018 | 19110051 | 7121000 |
| Tuesday, January 1, 2019 | 26556257 | 9128000 |
| Wednesday, January 1, 2020 | 52275890 | 10731000 |
| Friday, January 1, 2021 | 80981000 | 10701000 |
| Saturday, January 1, 2022 | 124431000 | 16121000 |
| Sunday, January 1, 2023 | 90932000 | 37021000 |
| Monday, January 1, 2024 | 98761000 |
Unleashing the power of data
In the competitive world of biotechnology, managing operational expenses is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Arrowhead Pharmaceuticals, Inc. and Viking Therapeutics, Inc., from 2014 to 2023.
Arrowhead Pharmaceuticals has shown a significant upward trend in SG&A expenses, peaking in 2022 with a 410% increase from 2014. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Viking Therapeutics, while also increasing their SG&A expenses, has maintained a more conservative growth, with a notable spike in 2023, marking a 290% rise since 2014.
The data suggests that Arrowhead's strategy leans towards rapid scaling, while Viking focuses on steady growth. Understanding these trends provides insights into each company's operational strategies and market positioning.
SG&A Efficiency Analysis: Comparing Novartis AG and Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Sanofi or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and Viking Therapeutics, Inc.
Incyte Corporation and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs Arrowhead Pharmaceuticals, Inc.
Axsome Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viking Therapeutics, Inc. and MorphoSys AG
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.
Viking Therapeutics, Inc. and Evotec SE: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and MiMedx Group, Inc.